Fred R Hirsch, MD, PhD
PROFESSOR | Medicine, Hematology and Medical Oncology
PROFESSOR | Pathology, Molecular and Cell Based Medicine
PROFESSOR | Medicine, Hematology and Medical Oncology
PROFESSOR | Pathology, Molecular and Cell Based Medicine
Research
Lung Cancer
Research Focus Dr. Hirsch’s career in lung cancer research spans more than 25 years and includes translational research, targeted therapies, and early detection of lung cancer. His research has helped identify and validate prognostic markers for lung cancer outcomes and biomarkers for personalized lung cancer therapies that illustrate how these therapies work and who is most likely to benefit from them.Education
MD, University of Copenhagen
PhD, University of Copenhagen
BA, University of Copenhagen Business School
Office Locations
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Below are financial relationships with industry reported by Dr. Hirsch during 2023 and/or 2024. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
- Regeneron Pharmaceuticals
- Daiichi-Sankyo Co., Ltd.
- Gerson Lehrman Group
- NextCure
- Merck & Co., Inc.
- Astrazeneca
- Blueprint Medicines
- Merus
- Novocure
- G1 Therapeutics
- MJH Life Sciences
- sanofi-aventis
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Below are financial relationships with industry reported by Dr. Hirsch during 2023 and/or 2024. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
- Regeneron Pharmaceuticals
- Daiichi-Sankyo Co., Ltd.
- Gerson Lehrman Group
- NextCure
- Merck & Co., Inc.
- Astrazeneca
- Blueprint Medicines
- Merus
- Novocure
- G1 Therapeutics
- MJH Life Sciences
- sanofi-aventis
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.